GSK's Triple Combo COPD Drug Gets Europe Okay
Executive Summary
Europe's regulators have followed their US counterparts and given the green light to GSK's Trelegy. Now the company is hoping that having the first once-daily single inhaler triple therapy for COPD will boost its respiratory business.
You may also be interested in...
Japanese OK In COPD Gives AstraZeneca’s Breztri Aerosphere First Regulatory Approval
AstraZeneca’s respiratory chief tells Scrip Japan’s approval of the triple-combination inhaled therapy is both a milestone for treating COPD and for the UK pharma’s strategy.
C4XD Delisting Highlights Funding Frustration For UK Biotechs
The Manchester-based group has had enough of being undervalued in the public markets and is going private again.
Novo Reaches Winning Post With Gamechanger Once-Weekly Insulin
The Danish drugmaker is cementing its leadership in diabetes with an imminent approval in Europe for Awiqli which reduces the number of basal insulin injections for patients from seven to just one per week.